Alembic Pharmaceuticals gets USFDA tentative nod for generic cancer treatment drug

Alembic Pharmaceuticals has secured tentative approval from the USFDA for its Bosutinib tablets. These tablets are used to treat certain types of cancer, specifically chronic myelogenous leukemia. The approval covers the 400 mg strength. This development marks a significant step for Alembic in the US market. The company previously received final approval for other strengths of the same drug.